291 related articles for article (PubMed ID: 20089807)
21. Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat.
Bouzom F; Laveille C; Merdjan H; Jochemsen R
J Pharm Sci; 2000 May; 89(5):603-13. PubMed ID: 10756326
[TBL] [Abstract][Full Text] [Related]
22. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG
Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378
[TBL] [Abstract][Full Text] [Related]
23. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
24. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
Meno-Tetang GM; Lowe PJ
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):182-92. PubMed ID: 15733213
[TBL] [Abstract][Full Text] [Related]
25. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
Daoussis D; Liossis SN; Solomou EE; Tsanaktsi A; Bounia K; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Arthritis Rheum; 2010 Jan; 62(1):150-8. PubMed ID: 20039407
[TBL] [Abstract][Full Text] [Related]
26. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
27. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
28. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.
Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2006 Nov; 319(2):682-92. PubMed ID: 16855177
[TBL] [Abstract][Full Text] [Related]
29. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
[TBL] [Abstract][Full Text] [Related]
31. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
Agoram BM
Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
[TBL] [Abstract][Full Text] [Related]
32. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
33. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
34. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
[TBL] [Abstract][Full Text] [Related]
35. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
Iwaniec UT; Yuan D; Power RA; Wronski TJ
J Bone Miner Res; 2006 Jul; 21(7):1068-74. PubMed ID: 16813527
[TBL] [Abstract][Full Text] [Related]
36. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
37. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
39. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
[TBL] [Abstract][Full Text] [Related]
40. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.
Aston PJ; Derks G; Raji A; Agoram BM; van der Graaf PH
J Theor Biol; 2011 Jul; 281(1):113-21. PubMed ID: 21557949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
